Angela Hwang - Pfizer Group President - Pfizer Essential Health
| PFE Stock | EUR 25.15 0.63 0.04% |
President
Ms. Angela Hwang is the Group President Pfizer Essential Health of the company effective January 1, 2018. She was served as Group President, Pfizer Essential Health from January 2018 until December 2018. Global President, Pfizer Inflammation and Immunology from January 2016 until December 2017. Regional Head, U.S. Vaccines from January 2014 until December 2015. Vice President, Emerging Markets for the Primary Care business from September 2011 until December 2013. Vice President, U.S. Brands business within Essential Health from October 2009 until August 2011. since 2018.
| Age | 57 |
| Tenure | 7 years |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1287 % which means that it generated a profit of $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3622 %, meaning that it generated $0.3622 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Pfizer Inc has accumulated 34.76 B in total debt with debt to equity ratio (D/E) of 78.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pfizer Inc has a current ratio of 1.51, which is within standard range for the sector. Debt can assist Pfizer until it has trouble settling it off, either with new capital or with free cash flow. So, Pfizer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pfizer Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pfizer to invest in growth at high rates of return. When we think about Pfizer's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Peter Fasolo | Johnson Johnson | 60 | |
Management Performance
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President - Global Established Pharma Business | ||
| Jennifer Damico, Controller VP | ||
| Christopher CFA, VP Officer | ||
| DVM DVM, Chairman CEO | ||
| Frank DAmelio, CFO, Executive Vice President - Business Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Mikael MD, Dev Research | ||
| David Denton, Chief VP |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 276.06 B | |||
| Shares Outstanding | 5.62 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 71.00 % | |||
| Price To Earning | 16.17 X | |||
| Price To Book | 3.13 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pfizer Stock
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.